Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
When you complete your Levity online questionnaire, our healthcare professionals will recommend the right weight loss treatment for you depending on your medical history
The key is to have maintainable weight at the time of surgery
Weight loss results compared: what the clinical data actually shows Numbers do not lie
Studies on the antidiabetic activities of Momordica charantia fruit juice in streptozotocin-induced diabetic rats